LSIPR roundtable

The US Patent and Trademark Office (USPTO) guidance on the patent eligibility of natural products in the US following the Myriad and Mayo court cases is fundamentally flawed, according to the life sciences IP experts invited to take part in the first LSIPR roundtable discussion held earlier this month in London.